Down-regulation of CD28, TCR-zeta (ζ) and up-regulation of FAS in peripheral cytotoxic T-cells of primary breast cancer patients

Anticancer Research

Volumn 28, Issue 2 A, 2008, Pages 779-784

  Gruber, I V ^a   El Yousfi, S ^a   Durr Storzer S ^a   Wallwiener, D ^a   Solomayer, E F ^a   Fehm, T ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Apoptosis; Breast cancer; CD28; FAS; Immune dysfunction; Immunosurveillance; T cell impairment; TCR zeta

Indexed keywords

CD28 ANTIGEN; FAS ANTIGEN; T CELL RECEPTOR ZETA CHAIN; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DOWN REGULATION; FEMALE; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; T LYMPHOCYTE ACTIVATION; UPREGULATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD28; ANTIGENS, CD95; B-LYMPHOCYTES; BREAST NEOPLASMS; DOWN-REGULATION; FEMALE; HUMANS; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MEMBRANE PROTEINS; MIDDLE AGED; MODELS, BIOLOGICAL; PROGNOSIS; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES, CYTOTOXIC; UP-REGULATION;

EID: 42549123152     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Burnet FM: The concept of immunological surveillance. Prog ExpTumor Res 13: 1-27, 1970.
2. + T lymphocytes in peripheral blood of patients with advanced melanoma. Clin Cancer Res 6: 1351-1364, 2000.
3. Whiteside TL and Parmiani G: Tumor-infiltrating lymphocytes: their phenotype, function and clinical use. Cancer Immunol Immunother 39: 15-21, 1994.
4. Campbell MJ, Scott J, Maecker HT, John WP and Esserman LJ: Immune dysfunction and micrometastases in women with breast cancer. Breast Cancer Res and Treat 91: 163-171, 2005.
5. Fehm T, Becker S, Pergola-Becker G, Kramer B, Gruber I, Sotlar K., Kurek R, Wallwiener D and Solomayer E: Influence of tumor biological factors on tumor cell dissemination in primary breast cancer. Anticancer Res 24(6): 4211-4216, 2004.
6. Wiedswang G, Borgen E, Schirmer C, Karesen R, Kvalheim G, Nesland JM and Naume B: Comparison of the clinical significance of occult tumor cells in blood and bone marrow in breast cancer. Int J Cancer 118(8): 2013-2019, 2006.
7. Rabinovich H, Reichert TE, Kashii Y, Gastmann BR, Bell MC and Whiteside TL: Lymphocyte apoptosis induced by Fas ligand-expressing ovarian carcinoma cells. Implications for altered expression of T cell receptor in tumor-associated lymphocytes. J Clin Invest 101: 2579-2588, 1998.
8. Strand S, Hofmann WJ, Hug H, Muller M, Otto G, Strand D, Mariani, SM, Stremmel W, Krammer PH and Galle PR: Lymphocyte apoptosis induced by CD95 (APO-1/FAS) ligand-expressing tumor cells-a mechanism of immune evasion? Nat Med 2: 1361-1366, 1997.
9. Dworacki G, Meidenbauer N, Kuss I, Hoffmann TK, Gooding W, Lotze M and Whiteside TL: Decreased zeta chain expression and apoptosis in CD3+ peripheral blood T lymphocytes of patients with melanoma. Clin Cancer Res 7: 947s-957s, 2007.
10. Hoffmann TK, Dworacki G, Tsukihiro T, Meidenbauer N, Gooding W, Johnson JT and Whiteside TL: Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance. Clin Cancer Res 8: 2553-2562, 2002.
11. Reichert TE, Strauss L, Wagner EM, Gooding W and Whiteside TL: Signaling abnormalities, apoptosis and reduced proliferation of circulating and tumor-infiltrating lymphocytes in patients with oral carcinoma. Clin Cancer Res 8: 3137-3145, 2002.
12. Rabinowich H, Reichert TE, Kashii Y, Gastman BR, Bell MC and Whiteside TL: Lymphocyte apoptosis induced by Fas ligand-expressing ovarian carcinoma cells. Implications for altered expression of T cell receptor in tumor-assocaited lymphocytes. J Clin Invest 101: 2579-2588, 1998.
13. Müschen M, Moers C, Warskulat U, Even J, Niederacher D and Beckmann MW: CD95 ligand expression as a mechanism of immune escape in breast cancer. Immunology 99: 69-77, 2000.
14. Nakagomi H, Petersson M, Magnusson I, Juhlin C, Matsuda M, Mellstedt H, Taupin JL, Vivier E, Anderson P and Kiessling R: Decreased expansion of the signal-transducing zeta chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma. Cancer Res 53: 5610-5612, 1993.
15. Blake-Mortimer JS, Sephton SE, Carlson RW, Stites D and Spiegel D: Cytotoxic T lymphocytes count and survival time in women with metastatic breast cancer. The Breast Journal 10(3): 195-199, 2004.
16. Mittrucker HW, Kursar M, Kohler A, Hurwitz R and Kaufmann SH: Role of CD28 for the generation and expansion of antigen-specific CD8 (+) T lymphocytes during infection with Listeria monocytogenes. J Immunol 167: 5620-5627, 2001.
17. Krinzman SJ, De Sanctis GT, Cernadas M, Mark D, Wang Y, Listman J, Kobzik L, Donovan C, Nassr K, Katona I, Christiani DC, Perkins DL and Finn PW: Inhibition of T cell costimulation abrogates airway hyperresponsiveness in a murine model. J Clin Invest 98: 2693-2699, 1996.
18. Lucas PJ, Negishi I, Nakayama K, Fields LE and Loh DY: Naïve CD28-deficient T cells can initiate but not sustain an in vitro antigen-specific immune response. J Immunol 154: 5757-5768, 1995.
19. Gudmundsdottir H, Wells AD and Turka LA: Dynamics and requirements of T cell clonal expansion in vivo at the single-cell level: effector function is linked to proliferation capacity. J Immunol 162: 5212-5223, 1999.
20. Samelson LE: Signal transduction mediated by T cell antigen receptor: the role of adapter proteins. Annu Rev Immunol 20: 371-394, 2002.
21. Bonnevier JL and Mueller DL: Cutting Edge: B7/CD28 interactions regulate cell cycle progression independent of the strength of TCR signalling. J Immunol 169: 6659-6663, 2002.
22. Michel F, Attal-Bonnefoy G, Mangino G, Mise-Omata S and Acuto O: CD28 as a molecular amplifier extending TCR ligation and signaling capabilities. Immunity 15: 935-945, 2001.
23. Germain RN and Stefanova I: The dynamics of T cell receptor signalling: complex orchestration and key roles of tempo and cooperation. Annu Rev Immunol 17: 467-522, 1999.
24. Kurt RA, Urba WJ, Smith JW and Schoof DD: Peripheral T lymphocytes from women with breast cancer exhibit abnormal protein expression of several signaling molecules. Int J Cancer 78(1): 16-20, 1998.
25. - T-cells have signalling defects in patients with head and neck cancer. Br J Cancer 88: 223-230, 2003.
26. Whiteside TL: Tumor-induced death of immune cells: its mechanism and consequences. Semin Cancer Biol 12: 43-50, 2002.
27. Kuss I, Saito T, Johnson JT and Whiteside TL: Clinical significance of decreased ζ chain expression in peripheral blood lymphocytes of patients with head and neck cancer. Clin Cancer Res 5: 329-334, 1999.
28. Walker LS, McLeod JD, Boulougouris G, Patel YI, Hall Nd and Sansom DM: Down-regulation of CD28 via Fas (CD95): influence of CD28 on T-cell apoptosis. Immunology 94(1): 41-47, 1998.